TY - JOUR
T1 - The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir
AU - Brennan, Daniel C.
AU - Storch, Gregory A.
AU - Singer, Gary G.
AU - Lee, Linda
AU - Rueda, Jose
AU - Schnitzler, Mark A.
N1 - Funding Information:
Received 1 December 1999; revised 27 January 2000; electronically published 8 May 2000. Presented in part: American Society of Transplantation, Chicago, May 1999 (abstract 484). Informed consent was obtained from all patients. This study was approved by and conducted according to the guidelines of the Human Studies Committee of the Washington University School of Medicine. Financial support: Missouri Kidney Program; Established Investigator grant of the American Heart Association (9940035N) (D.C.B.); Fraternal Order of Eagles (D.C.B.). No author has a commercial or other association that might pose a conflict of interest. a Present affiliation: West Florida Medical Center Clinic, Pensacola. Reprints or correspondence: Dr. Daniel C. Brennan, Washington University School of Medicine, Internal Medicine, Renal Dept., 6107 Queeny Tower, One Barnes-Jewish Hospital Plaza, St. Louis, MO 63110 (brennand @msnotes.wustl.edu).
PY - 2000
Y1 - 2000
N2 - The purpose of this study was to compare the prevalence of human herpesvirus (HHV)-7 and cytomegalovirus (CMV) viremia and the effects of oral and intravenous (iv) ganciclovir in renal transplant recipients at risk for CMV. Stored lysates from peripheral blood leukocytes from 92 patients, who had been previously analyzed for CMV viremia by polymerase chain reaction (PCR) for 12 weeks after transplantation, were analyzed for HHV-7 viremia. Baseline and peak prevalences of HHV-7 viremia were 22% and 54%, respectively (P < .0001). Eighty-two (89%) of 92 patients had at least 1 positive PCR for HHV-7. Oral ganciclovir and treatment with iv ganciclovir had no effect on the prevalence of HHV-7 viremia. In contrast, CMV was almost completely suppressed in patients who received oral ganciclovir, and when present, CMV responded to iv therapy. These results indicate that HHV-7 is resistant to ganciclovir at levels that were effective for prevention and treatment of CMV.
AB - The purpose of this study was to compare the prevalence of human herpesvirus (HHV)-7 and cytomegalovirus (CMV) viremia and the effects of oral and intravenous (iv) ganciclovir in renal transplant recipients at risk for CMV. Stored lysates from peripheral blood leukocytes from 92 patients, who had been previously analyzed for CMV viremia by polymerase chain reaction (PCR) for 12 weeks after transplantation, were analyzed for HHV-7 viremia. Baseline and peak prevalences of HHV-7 viremia were 22% and 54%, respectively (P < .0001). Eighty-two (89%) of 92 patients had at least 1 positive PCR for HHV-7. Oral ganciclovir and treatment with iv ganciclovir had no effect on the prevalence of HHV-7 viremia. In contrast, CMV was almost completely suppressed in patients who received oral ganciclovir, and when present, CMV responded to iv therapy. These results indicate that HHV-7 is resistant to ganciclovir at levels that were effective for prevention and treatment of CMV.
UR - http://www.scopus.com/inward/record.url?scp=0034043961&partnerID=8YFLogxK
U2 - 10.1086/315477
DO - 10.1086/315477
M3 - Article
C2 - 10823753
AN - SCOPUS:0034043961
SN - 0022-1899
VL - 181
SP - 1557
EP - 1561
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 5
ER -